Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study

Abstract Introduction Upadacitinib is an oral Janus kinase inhibitor approved in multiple countries for moderate-to-severe atopic dermatitis (AD). Here we present long-term data for up to 3 years of continuous upadacitinib treatment in Japanese patients with AD. Methods Rising Up was a phase 3, rand...

Full description

Bibliographic Details
Main Authors: Norito Katoh, Masanori Ikeda, Yukihiro Ohya, Hiroyuki Murota, Xiaofei Hu, John Liu, Hayato Niiyama, Takuya Sasaki, Eliza M. Raymundo, Hidehisa Saeki
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-12-01
Series:Dermatology and Therapy
Subjects:
Atopic dermatitis
Clinical trial
Eczema
Janus kinase inhibitors
Safety
Topical corticosteroids
Online Access:https://doi.org/10.1007/s13555-023-01071-2

Similar Items

Similar Items